Transposase Enabled CLD: High Titer From mAbs To Difficult To Express Proteins & Multi Chain Biologics

• Transposase mediated technology with high-performing cell pools
• High-throughput automation for faster clone selection/timelines to IND
• Highly customizable programs based on molecule type and program goals
• Built for any molecule, from mAbs to complex proteins

Cell Line Development for Antibodies and Complex Proteins

We aren't just a CDMO for standard antibodies, we also specialize in taking on the complex molecules (bispecifics, trispecifcs, FC-fusions, and more). With transposase mediated technology that offers more stable, better performing cell pools, we can increase productivity and genetic stability for the industry's most complex molecules and processes.

Highly Customizable Cell Line Development Services

We utilize optimal technology and processes built around a molecule's needs to get you to IND as fast as possible. Our program also features:

• Transfection to IND in 11 months
• Monoclonal antibody titers up to 8 grams / liter; complex proteins multichain molecules up to 4-8 grams / liter
• Transposase-mediated cell line technology with targeted integration & highly productive and stable pools
• Developability assessment to screen multiple protein variants upfront (with stable pool generation for each)
• Research cell bank (RCB), master cell bank (MCB), cGMP cell banking services

Protein Expression Processes Built with GMP Goals in Mind

Preparing proteins for manufacturing starts at the cell line development stage, and requires expertise, customization, and a clear plan to reach clinical manufacturing.

• Cell line development and process development scientists work collaboratively and use shared expertise to efficiently guide your molecule into GMP production
• Customized analytical formulation that includes early sequence and structural analysis for rapid analytics and analytical panels to assess risk and minimize issues at GMP stages
• We have fed-batch, perfusion, and N-1 perfusion manufacturing technology, guide your selection of production technology when you reach clinical manufacturing

Proven Transposase-Mediated Technology

We integrated ATUM's industry-leading Leap-In Transposase^® expression platform into our cell line development portfolio, giving us highly productive and stable pools that are predictive of final clone titers. This helps us begin process development work earlier and reduce stability screenings, helping accelerate timelines for your project.

• CLD technology that has supported 50+ IND filings
• Active in 40+ licenses on the market
• Approved in 3 global jurisdictions

Technologies that Enhance our CLD Capabilities

Beacon^® Technology

Automated single-cell cloning and high-throughput screening for early clone selection to increase productivity, shorten timelines, and subsequently create better bioprocess performance.

Ambr^® 250

Automated technology to rapidly screen the top four clones concurrently and generate stable pools for multiple variants, allowing for reduced process development timelines.

Excedion^™ Pro Mass Spectrometer

This mass spectrometry tech helps us quickly distinguish between different molecular species; a high scan rate allows us to collect data faster and support rapid turnaround times for CLD campaigns.